MX376515B - Método para reducir la muerte de células neuronales con haloalquilaminas. - Google Patents

Método para reducir la muerte de células neuronales con haloalquilaminas.

Info

Publication number
MX376515B
MX376515B MX2016002655A MX2016002655A MX376515B MX 376515 B MX376515 B MX 376515B MX 2016002655 A MX2016002655 A MX 2016002655A MX 2016002655 A MX2016002655 A MX 2016002655A MX 376515 B MX376515 B MX 376515B
Authority
MX
Mexico
Prior art keywords
cell death
neuronal cell
haloalkylamines
directed
methods
Prior art date
Application number
MX2016002655A
Other languages
English (en)
Spanish (es)
Other versions
MX2016002655A (es
Inventor
David J Poulsen
Thomas Frederick Rau
Original Assignee
The Univ Of Montana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Montana filed Critical The Univ Of Montana
Publication of MX2016002655A publication Critical patent/MX2016002655A/es
Publication of MX376515B publication Critical patent/MX376515B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016002655A 2013-09-06 2014-09-08 Método para reducir la muerte de células neuronales con haloalquilaminas. MX376515B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874865P 2013-09-06 2013-09-06
PCT/US2014/054569 WO2015035308A2 (en) 2013-09-06 2014-09-08 Method of reducing neuronal cell death with haloalkylamines

Publications (2)

Publication Number Publication Date
MX2016002655A MX2016002655A (es) 2016-06-06
MX376515B true MX376515B (es) 2025-03-07

Family

ID=52629091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002655A MX376515B (es) 2013-09-06 2014-09-08 Método para reducir la muerte de células neuronales con haloalquilaminas.

Country Status (7)

Country Link
US (3) US20160220515A1 (https=)
EP (1) EP3041465B1 (https=)
JP (3) JP6475733B2 (https=)
CN (2) CN105530924A (https=)
CA (1) CA2923476C (https=)
MX (1) MX376515B (https=)
WO (1) WO2015035308A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041465B1 (en) * 2013-09-06 2020-11-11 The University Of Montana Method of reducing neuronal cell death with haloalkylamines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5513661A (en) 1993-10-14 1996-05-07 Hubbard; David R. Use of sympathetic blockade for treatment of chronic muscle pain
US6009875A (en) 1993-10-14 2000-01-04 Berlex Laboratories, Inc. Use of sympathetic antagonists for treatment of chronic muscle pain
WO1997007793A1 (en) * 1995-08-29 1997-03-06 New York Medical College Formulations of haloalkylamines and local anaesthetics and methods for the treatment of reflex sympathetic dystrophy (rsd)
EP1235563A2 (en) 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
CA2416650C (en) 2000-07-19 2010-09-21 Pitmy International N.V. Enhancement of the action of central and peripheral nervous system agents
US6730667B2 (en) 2001-11-26 2004-05-04 William R. Deagle Iontophoresis disc pain blocker
US7172614B2 (en) * 2002-06-27 2007-02-06 Advanced Cardiovascular Systems, Inc. Support structures for embolic filtering devices
US20040063612A1 (en) * 2002-09-26 2004-04-01 Manssur Yalpani Neuroprotective agents
US7600349B2 (en) * 2003-02-26 2009-10-13 Unirac, Inc. Low profile mounting system
US20060128719A1 (en) * 2004-12-13 2006-06-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
WO2007057508A2 (en) 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
WO2007062862A2 (en) 2005-12-02 2007-06-07 Ludwig Maximilians Universität München Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
US20070249725A1 (en) 2006-02-17 2007-10-25 Hubbard David R Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain
MX2009001966A (es) 2006-08-23 2009-06-19 Univ Montana Metodo de reduccion del daño celular neuronal.
US20090197969A1 (en) * 2006-08-23 2009-08-06 Poulsen David J Method of reducing brain cell damage or death
US20110105621A1 (en) * 2006-08-23 2011-05-05 The University Of Montana Method of reducing brain cell damage, inflammation or death
ES2475193T3 (es) 2007-01-22 2014-07-10 Gtx, Inc. Agentes de unión al receptor nuclear
US8292830B2 (en) 2007-05-22 2012-10-23 University Of Louisville Research Foundation, Inc. Soft tissue impact assessment device and system
WO2010148519A1 (en) 2009-06-25 2010-12-29 Queen's University At Kingston Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist
CN102946896A (zh) * 2010-04-30 2013-02-27 西安大略大学 Sox9抑制剂
WO2012074561A2 (en) 2010-11-30 2012-06-07 Columbia Northwest Pharmaceuticals Llc Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders
EP2466311A1 (en) 2010-12-17 2012-06-20 Roche Diagnostics GmbH sFlt1 in patients with ischemic stroke
CA2768796A1 (en) 2011-02-22 2012-08-22 Wellspring Pharmaceutical Corporation Phenoxybenzamine assay
WO2012162364A1 (en) * 2011-05-23 2012-11-29 New York Medical College Phenoxybenzamine for pain
US20140371322A1 (en) 2013-06-13 2014-12-18 Professional Compounding Centers Of America Phenoxybenzamine Transdermal Composition
EP3041465B1 (en) 2013-09-06 2020-11-11 The University Of Montana Method of reducing neuronal cell death with haloalkylamines

Also Published As

Publication number Publication date
WO2015035308A3 (en) 2015-10-29
MX2016002655A (es) 2016-06-06
JP2019077718A (ja) 2019-05-23
EP3041465B1 (en) 2020-11-11
JP6636660B2 (ja) 2020-01-29
JP6865806B2 (ja) 2021-04-28
EP3041465A4 (en) 2017-03-08
US20210093586A1 (en) 2021-04-01
CN110251496A (zh) 2019-09-20
JP2016529320A (ja) 2016-09-23
EP3041465A2 (en) 2016-07-13
US20190083423A1 (en) 2019-03-21
CA2923476A1 (en) 2015-03-12
CN105530924A (zh) 2016-04-27
US10849865B2 (en) 2020-12-01
WO2015035308A2 (en) 2015-03-12
US20160220515A1 (en) 2016-08-04
JP2020059746A (ja) 2020-04-16
CA2923476C (en) 2021-03-16
JP6475733B2 (ja) 2019-02-27

Similar Documents

Publication Publication Date Title
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
CL2019001878A1 (es) Compuestos de microarn y métodos de modulación de la actividad de mir-21 (divisional solicitud 201402844).
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
UY34654A (es) Inhibidores de la beta-secretasa
PT3297644T (pt) Métodos para tratar distúrbios do espetro do autismo e sintomas associados
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
MX2021008755A (es) Un anticuerpo anti-tau para usarse al tratar una tauopatia.
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
MX373187B (es) Terapia de combinación para tratar cáncer.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
BR112014019357A8 (pt) Derivados de tetra-hidro- quinazolinona como inibidores de tanc e parp
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
MX2017011375A (es) Método para tratar un tumor cerebral.
NI202000029A (es) Amidas de imidazopiridina sustituidas y su uso
BR112015009130A2 (pt) derivados de 4-carboxamido-isoindolinona seletivos como inibidores de parp-1
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
BR112016025396A2 (pt) derivados de heterociclil-butanamida
MX2016007803A (es) Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
UY34991A (es) Inhibidores de la beta-secretasa
MX2017009608A (es) Compuestos anticancerigenos.

Legal Events

Date Code Title Description
FG Grant or registration